Skip to Main Navigation Skip to Content
Collaborative global initiatives in science

Main Content

 

XIX International Symposium on Respiratory Viral Infections

June 22-25, 2017 Berlin, Germany

Preliminary Program/ Invited Speakers

As of June 2, 2017

Chairs

Abdullah Brooks

The Bloomberg School for Public Health, Department of International Health, Johns Hopkins University, Baltimore, Maryland, United States

Arnold Monto

Thomas Francis Jr Professor of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States

Albert Osterhaus

Artemis One Health, Utrecht, The Netherlands; and University Veterinary Medicine Hannover, Germany

 

Scientific Advisory Board:
Menno de Jong Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Daniel Feikin Consultant, World Health Organization, United States
Bradford Gessner Scientific Director, Agence de Medecine Preventitive, Paris, France
Kathy Neuzil University of Maryland School of Medicine, Baltimore, Maryland, United States

 

Thursday, June 22, 2017
15:00 – 18:00 Afternoon Registration
Friday, June 23, 2017 – Day One
7:00 Registration Opens
8:45 Welcome and Introduction to Keynote
8:50 – 9:30 Keynote Address: Novel Intervention Strategies for Respiratory Viruses  Adolfo Garcia-Sastre, Director, Global Health and Emerging Pathogens Institute Icahn School of Medicine at Mount Sinai, New York, NY, United States (confirmed)
Session I Intervention Strategies for RSV – Chair: Daniel Feikin, Consultant, World Health Organization, United States (confirmed)
9:30 – 9:55 Overview of RSV: Intervention, Vaccination and Therapy – Daniel Feikin, Consultant, World Health Organization, United States (confirmed)
9:55 – 10:20 Role of Antibodies in Prevention and Treatment of RSV – Tonya Villafana, Senior Director, MedImmune, Gaithersburg, MD, United States (confirmed)
10:20 – 10:45 Management of RSV of Adults – Ann R. Falsey, M.D., University of Rochester, School of Medicine, NY, United States (confirmed)
10:45 – 11:10 Coffee Break
11:10 – 11:30 Oral Presentation: Functional Inactivation of Cellular Gatekeeper p53 During the Time Course of Respiratory Syncytial Virus Infection – Daniela Bandeira Machado, Foundation Merieux, Lyon, France
11:30 – 11:50 Oral Presentation: Harmonization of RSV Antibody Assays for Assessment of Vaccine Immunogenicity – Deborah Higgins, PATH Center for Vaccine Innovation and Access, Seattle, Washington, United States
11:50 – 12:10 Oral Presentation: An Observational Study to Assess Respiratory Syncytial Virus (RSV)-associated Illness in Adults with Chronic Obstructive Pulmonary Disease (COPD) and/or Congestive Heart Failure (CHF) – Ann R. Falsey, M.D., University of Rochester, School of Medicine, NY, United States (confirmed)
12:10 – 12:30 Oral Presentation and Young Investigator Award Recipient: Incidence of Influenza Infection and Re-infection over 6 Years of Prospective Household Follow-up – Joshua Petrie, University of Michigan, Ann Arbor, Michigan, United States (confirmed)
12:30 -12:50 Oral Presentation: RSV F Vaccine: The Development Pathway Leading to PREPARE: a Global, Multiple-Year Phase 3 Infant Via Maternal Clinical Trial – Gregory Glenn, President, Research & Development, Novavax, Gaithersburg, MD, United States (confirmed)
12:50 -14:40 Lunch
Session II Development and Introduction of New Vaccines – Chair: Arnold Monto, Thomas Francis Jr Professor of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States (confirmed)
14:40 – 15:05 The Use of Adjuvanted Vaccines. Pros and Cons. – Mark Doherty, Senior Medical Manager, GSK Vaccines, Brøndby, Denmark (confirmed)
15:05 – 15:30 Quadrivalent Influenza Vaccines – Arnold Monto, Thomas Francis Jr Professor of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States (confirmed)
15:30 – 15:55 Should Influenza Vaccine Contain Neuraminidase – Manon Cox, President and CEO, Protein Sciences Corporation (confirmed)
15:55 – 16:20 Recent Experience of LAIV in School Children in the UK – Richard Pebody, Department of Respiratory Diseases, Health Protection Agency, London, United Kingdom (Confirmed)
16:20 – 16:45 Coffee Break
16:45 – 17:05 Oral Presentation: Safety and Immunogenicity of Ad26 and Ad35 adenoviral vectored RSV vaccines Hester van Zeeburg, Janssen Vaccines & Prevention, Leiden, The Netherlands
17:05 – 17:35 Oral Presentation: A Phase 2b Study of MEDI7510, an Adjuvanted Post-fusion F Vaccine for the Prevention of RSV in Older Adults – Judith Falloon, MedImmune, Gaithersburg, MD, United States
18:00 – 19:30 Welcome Reception
Saturday, June 24, 2017 – Day Two
Session III Vaccination Programs for Prevention of Respiratory Infections – Chair: Kathy Neuzil, University of Maryland School of Medicine, Baltimore, Maryland, United States (confirmed)
10:00 – 10:25 Global Disease Burden of Influenza and RSV – Kathy Neuzil, University of Maryland School of Medicine, Baltimore, Maryland, United States (confirmed)
10:25 – 10:50 Challenges in Vaccine Virus Selection and Vaccine Coverage – Daniel Jernigan, Director, Influenza Division in the National Center for Immunization and Respiratory Diseases, U.S. Center for Disease Control, Atlanta, GA, United States (confirmed)
10:50 – 11:10 Oral Presentation: Vaccinated Individuals Were Infected with Influenza A(H3N2) Virus: Amino Acid Substitution Patterns Mark the Beginning of 2016-2017 Winter Season – Michal Mandelboim, Sheba Medical Center, Ramat Gan, Israel
Session IV New Approaches to Vaccine Use – Chair: Bradford Gessner, Scientific Director, Agence de Medecine Preventitive, Paris, France (confirmed)
11:10 – 11:35 Direct and Indirect Affects of Vaccination – Bradford Gessner, Scientific Director, Agence de Medecine Preventitive, Paris, France (confirmed)
11:35 – 12:00 Oral Presentation and Young Investigator Award Recipient: Travellers and Influenza: Risks and Prevention – Marco Goeijenbier, European Scientific Working Group on Influenza, Laarne, Belgium
12:00 – 14:00 Lunch
14:00 – 14:45 Roundtable Discussion: Current Vaccines and Future Vaccine Development

  • Abdullah Brooks, The Bloomberg School for Public Health, Department of International Health, Johns Hopkins University, Baltimore, Maryland, United States (confirmed)
  • Bradford Gessner, Scientific Director, Agence de Medecine Preventitive, Paris, France (confirmed)
  • Arnold Monto, Thomas Francis Jr Professor of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States (confirmed)
  • Kathy Neuzil, University of Maryland School of Medicine, Baltimore, Maryland, United States (confirmed)
  • Albert Osterhaus, Artemis One Health, Utrecht, The Netherlands; and University Veterinary Medicine Hannover, Germany (confirmed)
14:45 – 15:15 Poster Review by Albert Osterhaus
15:15 – 16:15 Poster Session Reception
Sunday, June 25, 2017 – Day Three
Session V Addressing Emerging and Re-Emerging Threats – Chair: Albert Osterhaus, Artemis One Health, Utrecht, The Netherlands; and University Veterinary Medicine Hannover, Germany (confirmed)
9:00 – 9:25 Emerging and Re-Emerging Threats by Respiratory Viruses – Albert Osterhaus, Artemis One Health, Utrecht, The Netherlands; and University Veterinary Medicine Hannover, Germany (confirmed)
9:25 – 9:50 Current Nipah Threat: Where do we stand? – Heinz Feldmann, National Institute of Health, Intramural Research Program, Hamilton, MT, United States (confirmed)
9:50 – 10:10 Current Avian Influenza Outbreaks. – Are they a Risk to Humans? – Martin Beer, Institutleiter, Friedrich Loeffler Institut, Greifswald-Insel Riems, Germany (confirmed)
10:10 – 10:30 Major Viral Threat from Bats – Christen Drosten, Charite – Univeritätsmedizin Berlin, Berlin, Germany (invited)
10:30 – 10:50 Oral Presentation: Burden of Disease: Estimates of Influenza-associated Mortality in Egypt 2000-2013 – Eman Aly, World Health Organization. Cairo, Egypt
10:50 – 11:20 Coffee Break
11:20 – 11:40 Oral Presentation and Young Investigator Award Recipient: Genomic Characterization of a Novel Human Influenza A(H1N2) variant detected in Brazil – Paola Cristina Resende, Oswaldo Cruz Institute, Rio de Janeiro, Brazil
11:40 – 12:00 Oral Presentation and Young Investigator Award Recipient: Viral Shedding Dynamics of Rhinovirus, Coronavirus and Respiratory Syncytial Virus in Adult Invasively Ventilated Critical ill PatientsFrank Van Someren Gréve, Department of Medical Microbiology, Academic Medical Center, Amsterdam, The Netherlands
Session VI Antivirals and Other Treatment Options – Chair: Menno de Jong, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (confirmed)
12:00 – 12:25 Overview of Flu: Where do we Stand Today? – Melissa Willis, Therapeutic Branch, BARDA, U.S. Department of Health and Human Services, Washington D.C., United States (confirmed)
12:25 – 14:25 Lunch
14:25 – 14:50 Combination Therapy and Other New Developments in Antiviral Treatment: Where are we in phase II and III studies? – Menno de Jong, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (confirmed)
14:50 – 15:10 Oral Presentation: EDP-938, a Novel Non-Fusion Replication Inhibitor of Respiratory Syncytial Virus, Demonstrates Potent Antiviral Activities both In Vitro and In Vivo – Kai Lin, Enanta Pharmaceuticals, Watertown, MA, United States
145:10 – 15:30 Oral Presentations: The Topaz Trial: A phase 2b Study of Pimodivir (jnj-63623872 or jnj-872; formerly vx-787) as Monotherapy or in Combination with Oseltamivir in the Treatment of Acute Uncomplicated Seasonal Influenza –  Roman Fleischhackl, Janssen-Cilag, Vienna, Austria
15:30 – 16:10 Panel Discussion – Chair: Abdullah Brooks, The Bloomberg School for Public Health, Department of International Health, Johns Hopkins University, Baltimore, Maryland, United States (confirmed) –  Including:
  • Daniel Feikin, Consultant, World Health Organization, United States
  • Arnold Monto, Thomas Francis Jr Professor of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States
  • Kathy Neuzil, University of Maryland School of Medicine, Baltimore, Maryland, United States
  • Bradford Gessner, Scientific Director, Agence de Medecine Preventitive, Paris, France
  • Albert Osterhaus, Artemis One Health, Utrecht, The Netherlands; and University Veterinary Medicine Hannover, Germany
  • Menno de Jong, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
16:10 – 16:20  Closing Remarks


Register Here